There is one clinical trial.
This is a phase I prospective, open-labeled, single-center study to evaluate the safety and immunogenicity of MVC-COV1901.
Description: Incidence of solicited adverse events (AEs) after vaccination, Incidence of unsolicited AEs and other AEs after vaccination, Incidence of laboratory abnormality after vaccination, Incidence of adverse event of special interest (AESI) and serious adverse events (SAEs) after vaccinationMeasure: Safety of MVC-COV1901 Time: Day 1 to 28 days after second vaccination
Description: Geometric mean titer (GMT), Seroconversion rate (SCR), and GMT ratioMeasure: Immunogenicity (neutralizing antibody titers and antigen specific binding antibody titers) Time: 14 days, 28 days after each vaccination, and 180 days after second vaccination.
Description: The positive rate of cellular mediated immune responseMeasure: Immunogenicity (antigen specific cellular immune responses) Time: 28 days and 180 days after second vaccination
Description: Incidence of other adverse events, Incidence of adverse event of special interest (AESI) and serious adverse events (SAEs) within the study periodMeasure: Safety of MVC-COV1901 Time: Day 1 to Day 209
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports